India’s Price Control Axe May Be Held Back For Now
This article was originally published in PharmAsia News
Executive Summary
India moves to cut prices on several diabetes and cardiovascular brands. But the pace of cuts by the price regulator on other drugs is expected to be measured as industry battles back on cancer, asthma, malaria and immunological drugs.